UK markets closed

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
44.04+0.64 (+1.47%)
As of 12:27PM EDT. Market open.

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht 3584 CT
31 30 253 8800

Full-time employees172

Key executives

NameTitlePayExercisedYear born
Dr. Sven Ante Lundberg M.D.CEO, President & Executive Director1.11MN/A1963
Mr. Gregory D. PerryChief Financial Officer419.1kN/A1960
Mr. Peter B. Silverman J.D.EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal781.84k565.02k1978
Dr. Hui Liu Ph.D.Chief Business Officer, Executive VP & Head of Merus U.S.640.14k1.8M1967
Dr. Andrew Joe M.D.Chief Medical Officer & Senior VP685.12kN/A1967
Dr. Hennie HoogenboomCo-Founder and Scientific AdvisorN/AN/AN/A
Harry ShumanChief Accounting OfficerN/AN/AN/A
Mr. Cornelis Adriaan de Kruif Ph.D.CTO & Executive VP351.59kN/A1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.Chief Scientific Officer & Senior VPN/AN/AN/A
Kathleen FarrenIR & Corporate Communications OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate governance

Merus N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.